Skip to content
TrackPodcasts
scienceMay 28, 202526:00pending

Ozempic: The science behind this blockbuster drug and its untapped potential

Tiny Matters

About this episode

In December 2017, the FDA approved a new injectable drug to treat type 2 diabetes called semaglutide, which you likely know by its brand name: Ozempic. A few years later, during the pandemic, Wegovy, a drug with a higher dose of the same active ingredient, was approved specifically for chronic weight management. Soon after, people taking Ozempic started reporting a dramatic, even “life-changing” weight loss. Ozempic is now a bona fide blockbuster. So what’s the science behind these “wonder drugs” that apparently 1 in 10 of us could end up using? They have the potential to have so many positive effects on our lives, from treating Alzheimer’s disease and addiction to changing our relationship with consumption but, like with most things, they also come with risks.

Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!

Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Get every episode summarized

Each time Tiny Matters publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

Ozempic: The science behind this blockbuster drug and its untapped potential

Tiny Matters

0:00
26:00

More episodes

More from Tiny Matters

View all episodes →